Title: Increased expression of distinct galectins in multiple sclerosis lesions
Abstract: Neuropathology and Applied NeurobiologyVolume 37, Issue 6 p. 654-671 Increased expression of distinct galectins in multiple sclerosis lesions M. Stancic, M. Stancic Department of Cell Biology, Section Membrane Cell Biology, University Medical Center Groningen, University of Groningen, GroningenSearch for more papers by this authorJ. van Horssen, J. van Horssen Departments of Neuropathology Molecular Cell Biology and ImmunologySearch for more papers by this authorV. L. Thijssen, V. L. Thijssen Medical Oncology and Radiotherapy, Angiogenesis Laboratory, VU University Medical Center, Amsterdam, The NetherlandsSearch for more papers by this authorH.-J. Gabius, H.-J. Gabius Institute of Physiological Chemistry, Faculty of Veterinary Medicine, Ludwig-Maximilians University Munich, Munich, GermanySearch for more papers by this authorP. van der Valk, P. van der Valk Departments of NeuropathologySearch for more papers by this authorD. Hoekstra, D. Hoekstra Department of Cell Biology, Section Membrane Cell Biology, University Medical Center Groningen, University of Groningen, GroningenSearch for more papers by this authorW. Baron, Corresponding Author W. Baron Department of Cell Biology, Section Membrane Cell Biology, University Medical Center Groningen, University of Groningen, GroningenWia Baron, Department of Cell Biology, Section Membrane Cell Biology, University Medical Center Groningen, University of Groningen, A. Deusinglaan 1, 9713 AV Groningen, The Netherlands. Tel: +31 503632737; Fax: +31 503632728; E-mail: [email protected]Search for more papers by this author M. Stancic, M. Stancic Department of Cell Biology, Section Membrane Cell Biology, University Medical Center Groningen, University of Groningen, GroningenSearch for more papers by this authorJ. van Horssen, J. van Horssen Departments of Neuropathology Molecular Cell Biology and ImmunologySearch for more papers by this authorV. L. Thijssen, V. L. Thijssen Medical Oncology and Radiotherapy, Angiogenesis Laboratory, VU University Medical Center, Amsterdam, The NetherlandsSearch for more papers by this authorH.-J. Gabius, H.-J. Gabius Institute of Physiological Chemistry, Faculty of Veterinary Medicine, Ludwig-Maximilians University Munich, Munich, GermanySearch for more papers by this authorP. van der Valk, P. van der Valk Departments of NeuropathologySearch for more papers by this authorD. Hoekstra, D. Hoekstra Department of Cell Biology, Section Membrane Cell Biology, University Medical Center Groningen, University of Groningen, GroningenSearch for more papers by this authorW. Baron, Corresponding Author W. Baron Department of Cell Biology, Section Membrane Cell Biology, University Medical Center Groningen, University of Groningen, GroningenWia Baron, Department of Cell Biology, Section Membrane Cell Biology, University Medical Center Groningen, University of Groningen, A. Deusinglaan 1, 9713 AV Groningen, The Netherlands. Tel: +31 503632737; Fax: +31 503632728; E-mail: [email protected]Search for more papers by this author First published: 19 April 2011 https://doi.org/10.1111/j.1365-2990.2011.01184.xCitations: 59Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Abstract M. Stancic, J. van Horssen, V. L. Thijssen, H.-J. Gabius, P. van der Valk, D. Hoekstra and W. Baron (2011) Neuropathology and Applied Neurobiology37, 654–671 Increased expression of distinct galectins in multiple sclerosis lesions Aims: Multiple sclerosis (MS) is a chronic progressive degenerative disorder of the central nervous system, characterized by inflammation, demyelination, ultimate failure of remyelination and axonal loss. Current research identifies galectins, adhesion/growth-regulatory effectors binding β-galactosides, peptide motifs and lipids, as important immunomodulators in diverse inflammatory diseases. However, little is known about their expression, cellular localization and role in human central nervous system tissue. To identify a potential role of galectins in MS, their expression and localization in control white matter (CWM) and demyelinated MS lesions were examined. Methods: qPCR, Western blot and immunohistochemical analyses were performed on human post mortem CWM and MS lesions at different stages. Cultured astrocytes, derived from healthy subjects and MS patients, were analysed similarly. Results: Among 11 different galectins tested, galectins-1, -3, -8 and -9 were present at detectable levels in CWM, and, interestingly, significantly enhanced in active MS lesions. On the cellular level, galectins localized to microglia/macrophages, astrocytes and endothelial cells. Intriguingly, galectin-9 displayed a distinctly different intracellular localization in microglia/macrophages when comparing active and inactive MS lesions, being restricted to the nuclei in active lesions, and primarily localizing in the cytoplasm in inactive lesions. Furthermore, enhanced levels of galectin-1, detected as dimers in Western blot analysis, were released by cultured astrocytes from MS patients. Conclusions: This study provides a detailed analysis of galectins in MS lesions and assigns distinct galectins to different aspects of the disease. Thus, besides being known as modulators of inflammatory processes, our findings suggest additional association of distinct galectins with MS pathology. References 1 Frohman EM, Racke MK, Raine CS. Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med 2006; 354: 942–55 2 Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372: 1502–17 3 Franklin RJ, ffrench-Constant C. Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci 2008; 9: 839–55 4 Goldschmidt T, Antel J, Konig FB, Bruck W, Kuhlmann T. Remyelination capacity of the MS brain decreases with disease chronicity. Neurology 2009; 72: 1914–21 5 Franklin RJ, Kotter MR. The biology of CNS remyelination: the key to therapeutic advances. J Neurol 2008; 255 (Suppl. 1): 19–25 6 Gabius HJ (Ed.). The Sugar Code. Fundamentals of Glycoscience. Weinheim, Germany: Wiley-VCH, 2006 7 Gabius HJ, Wu AM. The emerging functionality of endogenous lectins: a primer to the concept and a case study on galectins including medical implications. Chang Gung Med J 2006; 29: 37–62 8 Rotblat B, Niv H, André S, Kaltner H, Gabius HJ, Kloog Y. Galectin-1 (L11A) predicted from a computed galectin-1 farnesyl-binding pocket selectively inhibits Ras-GTP. Cancer Res 2004; 64: 3112–18 9 Barondes SH, Cooper DN, Gitt MA, Leffer H. Galectins. Structure and function of a large family of animal lectins. J Biol Chem 1994; 269: 20807–10 10 Kopitz J, von Reitzenstein C, André S, Kaltner H, Uhl J, Ehemann V, Cantz M, Gabius HJ. Negative regulation of neuroblastoma cell growth by carbohydrate-dependent surface binding of galectin-1 and functional divergence from galectin-3. J Biol Chem 2001; 276: 35917–23 11 Sanchez-Ruderisch H, Fischer C, Detjen KM, Welzel M, Wimmel A, Manning JC, André S, Gabius HJ. Tumor suppressor p16INK4a – downregulation of galectin-3, an endogenous competitor of the pro-anoikis effector galectin-1, in a pancreatic carcinoma model. FEBS J 2010; 277: 3552–63 12 Solis D, Mate MJ, Lohr M, Ribeiro JP, Lopez-Merino L, Andre S, Buzamet E, Canada FJ, Kaltner H, Lensch M, Ruiz FM, Haroske G, Wollina U, Kloor M, Kopitz J, Saiz JL, Menendez M, Jiménez-Barbero J, Romero A, Gabius HJ. N-domain of human adhesion/growth-regulatory galectin-9: preference for distinct conformers and non-sialylated N-glycans and detection of ligand-induced structural changes in crystal and solution. Int J Biochem Cell Biol 2010; 42: 1019–29 13 Hernandez JD, Baum LG. Ah, sweet mystery of death! Galectins and control of cell fate. Glycobiology 2002; 12: 127R–36R 14 Brewer CF, Miceli MC, Baum LG. Clusters, bundles, arrays and lattices: novel mechanisms for lectin-saccharide-mediated cellular interactions. Curr Opin Struct Biol 2002; 12: 616–23 15 Liu FT, Patterson RJ, Wang JL. Intracellular functions of galectins. Biochim Biophys Acta 2002; 1572: 263–73 16 Hsu DK, Liu FT. Regulation of cellular homeostasis by galectins. Glycoconj J 2004; 19: 507–15 17 Delacour D, Koch A, Jacob R. The role of galectins in protein trafficking. Traffic 2009; 10: 1405–13 18 Lahm H, Andre S, Hoeflich A, Fischer JR, Sordat B, Kaltner H, Wolf E, Gabius HJ. Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures. J Cancer Res Clin Oncol 2001; 127: 375–86 19 Langbein S, Brade J, Badawi JK, Hatzinger M, Kaltner H, Lensch M. Specht K, André S, Brinck U, Alken P, Gabius HJ. Gene-expression signature of adhesion/growth-regulatory tissue lectins (galectins) in transitional cell cancer and its prognostic relevance. Histopathology 2007; 51: 681–90 20 Cludts S, Decaestecker C, Mahillon V, Chevalier D, Kaltner H, André S, Remmelink M, Leroy X, Gabius HJ, Saussez S. Galectin-8 up-regulation during hypopharyngeal and laryngeal tumor progression and comparison with galectin-1, -3 and -7. Anticancer Res 2009; 29: 4933–40 21 Cada Z, Smetana K Jr, Lacina L, Plzáková Z, Stork J, Kaltner H, Russwurm R, Lensch M, André S, Gabius HJ. Immunohistochemical fingerprinting of the network of seven adhesion/growth-regulatory lectins in human skin and detection of distinct tumour-associated alterations. Folia Biol (Praha) 2009; 55: 145–52 22 Rabinovich GA, Toscano MA. Turning 'sweet' on immunity: galectin-glycan interactions in immune tolerance and inflammation. Nat Rev Immunol 2009; 9: 338–52 23 Bianco GA, Toscano MA, Ilarregui JM, Rabinovich GA. Impact of protein-glycan interactions in the regulation of autoimmunity and chronic inflammation. Autoimmun Rev 2006; 5: 349–56 24 Offner H, Celnik B, Bringman TS, Casentini-Borocz D, Nedwin GE, Vandenbark AA. Recombinant human beta-galactoside binding lectin suppresses clinical and histological signs of experimental autoimmune encephalomyelitis. J Neuroimmunol 1990; 28: 177–84 25 Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, Zheng XX, Strom TB, Kuchroo VK. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005; 6: 1245–52 26 Wang J, Lu ZH, Gabius HJ, Rohowsky-Kochan C, Ledeen RW, Wu G. Cross-linking of GM1 ganglioside by galectin-1 mediates regulatory T cell activity involving TRPC5 channel activation: possible role in suppressing experimental autoimmune encephalomyelitis. J Immunol 2009; 182: 4036–45 27 Toscano MA, Bianco GA, Ilarregui JM, Croci DO, Correale J, Hernandez JD, Zwirner NW, Poirier F, Riley EM, Baum LG, Rabinovich GA. Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat Immunol 2007; 8: 825–34 28 Jiang HR, Al Rasebi Z, Mensah-Brown E. Galectin-3 deficiency reduces the severity of experimental autoimmune encephalomyelitis. J Immunol 2009; 182: 1167–73 29 Lutomski D, Joubert-Caron R, Lefebure C, Lefebure C, Salama J, Belin C, Bladier D, Caron M. Anti-galectin-1 autoantibodies in serum of patients with neurological diseases. Clin Chim Acta 1997; 262: 131–8 30 De Groot CJ, Bergers E, Kamphorst W, Ravid R, Polman CH, Barkhof F, van der Valk P. Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: increased yield of active demyelinating and (p)reactive lesions. Brain 2001; 124: 1635–45 31 Maier O, Baron W, Hoekstra D. Reduced raft-association of NF155 in active MS-lesions is accompanied by the disruption of the paranodal junction. Glia 2007; 55: 885–95 32 Bsibsi M, Ravid R, Gveric D, van Noort JM. Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neuro 2002; 61: 1013–21 33 Klunder B, Baron W, Schrage C, de Jonge J, de Vries H, Hoekstra D. Sorting signals and regulation of cognate basolateral trafficking in myelin biogenesis. J Neurosci Res 2008; 86: 1007–16 34 Thijssen VL, Hulsmans S, Griffioen AW. The galectin profile of the endothelium: altered expression and localization in activated and tumor endothelial cells. Am J Pathol 2008; 172: 545–53 35 Andre S, Kojima S, Yamazaki N, Fink C, Kaltner H, Kayser K, Gabius HJ. Galectins-1 and -3 and their ligands in tumor biology. Non-uniform properties in cell-surface presentation and modulation of adhesion to matrix glycoproteins for various tumor cell lines, in biodistribution of free and liposome-bound galectins and in their expression by breast and colorectal carcinomas with/without metastatic propensity. J Cancer Res Clin Oncol 1999; 125: 461–74 36 Massardo L, Metz C, Pardo E, Mezzano V, Babul M, Jarpa E, Guzman AM, Andre S, Kaltner H, Gabius HJ, Jacobelli S, Gonzalez A, Soza A. Autoantibodies against galectin-8: their specificity, association with lymphopenia in systemic lupus erythematosus and detection in rheumatoid arthritis and acute inflammation. Lupus 2009; 18: 539–46 37 Lensch M, Lohr M, Russwurm R, Vidal M, Kaltner H, Andre S, Gabius HJ. Unique sequence and expression profiles of rat galectins-5 and -9 as a result of species-specific gene divergence. Int J Biochem Cell Biol 2006; 38: 1741–58 38 Kaltner H, Seyrek K, Heck A, Sinowatz F, Gabius HJ. Galectin-1 and galectin-3 in fetal development of bovine respiratory and digestive tracts. Comparison of cell type-specific expression profiles and subcellular localization. Cell Tissue Res 2002; 307: 35–46 39 Nagy N, Bronckart Y, Camby I, Legendre H, Lahm H, Kaltner H, Hadari Y, van Ham P, Yeaton P, Pector JC, Zick Y, Salmon I, Danguy A, Kiss R, Gabius HJ. Galectin-8 expression decreases in cancer compared with normal and dysplastic human colon tissue and acts significantly on human colon cancer cell migration as a suppressor. Gut 2002; 50: 392–401 40 Andre S, Sanchez-Ruderisch H, Nakagawa H, Buchholz M, Kopitz J, Forberich P, Kemmner W, Bock C, Deguchi K, Detjen KM, Wiedenmann B, von Knebel Doeberitz M, Gress TM, Nishimura S, Rosewicz S, Gabius HJ. Tumor suppressor p16INK4a–modulator of glycomic profile and galectin-1 expression to increase susceptibility to carbohydrate-dependent induction of anoikis in pancreatic carcinoma cells. FEBS J 2007; 274: 3233–56 41 van Horssen J, Vos CM, Admiraal L, van Haastert ES, Montagne L, van der Valk P, de Vries HE. Matrix metalloproteinase-19 is highly expressed in active multiple sclerosis lesions. Neuropathol Appl Neurobiol 2006; 32: 585–93 42 Nishi N, Itoh A, Shoji H, Miyanaka H, Nakamura T. Galectin-8 and galectin-9 are novel substrates for thrombin. Glycobiology 2006; 16: 15C–20C 43 Witte ME, Bo L, Rodenburg RJ, Belien JA, Musters R, Hazes T, Wintjes LT, Smeitink JA, Geurts JJ, de Vries HE, van der Valk P, van Horssen J. Enhanced number and activity of mitochondria in multiple sclerosis lesions. J Pathol 2009; 219: 193–204 44 Hughes RC. Secretion of the galectin family of mammalian carbohydrate-binding proteins. Biochim Biophys Acta 1999; 1473: 172–85 45 Saussez S, Decaestecker C, Lorfevre F, Chevalier D, Mortuaire G, Kaltner H, Andre S, Toubeau G, Gabius HJ, Leroy X. Increased expression and altered intracellular distribution of adhesion/growth-regulatory lectins galectins-1 and -7 during tumour progression in hypopharyngeal and laryngeal squamous cell carcinomas. Histopathology 2008; 52: 483–93 46 Cludts S, Decaestecker C, Mahillon V, Chevalier D, Kaltner H, Andre S, Remmelink M, Leroy X, Gabius HJ, Saussez S. Galectin-8 up-regulation during hypopharyngeal and laryngeal tumor progression and comparison with galectin-1, -3 and -7. Anticancer Res 2009; 29: 4933–40 47 Dore-Duffy P, Washington R, Dragovic L. Expression of endothelial cell activation antigens in microvessels from patients with multiple sclerosis. Adv Exp Med Biol 1993; 331: 243–8 48 Thijssen VL, Poste R, Brandwijk RJ, Dings RP, Nesmelova I, Satijn S, Verhofstad N, Nakabeppu Y, Baum LG, Bakkers J, Mayo KH, Poirier F, Griffioen AW. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci USA 2006; 103: 15975–80 49 Saal I, Nagy N, Lensch M, Lohr M, Manning JC, Decaestecker C, Andre S, Kiss R, Salmon I, Gabius HJ. Human galectin-2: expression profiling by RT-PCR/immunohistochemistry and its introduction as a histochemical tool for ligand localization. Histol Histopathol 2005; 20: 1191–208 50 Camby I, Belot N, Rorive S, Lefranc F, Maurage CA, Lahm H, Kaltner H, Hadari Y, Ruchoux MM, Brotchi J, Zick Y, Salmon I, Gabius HJ, Kiss R. Galectins are differentially expressed in supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas, and significantly modulate tumor astrocyte migration. Brain Pathol 2001; 11: 12–26 51 Sato S, Hughes RC. Regulation of secretion and surface expression of Mac-2, a galactoside-binding protein of macrophages. J Biol Chem 1994; 269: 4424–30 52 Walther M, Kuklinski S, Pesheva P, Guntinas-Lichius O, Angelov DN, Neiss WF, Asou H, Probstmeier R. Galectin-3 is upregulated in microglial cells in response to ischemic brain lesions, but not to facial nerve axotomy. J Neurosci Res 2000; 61: 430–5 53 Reichert F, Rotshenker S. Galectin-3/MAC-2 in experimental allergic encephalomyelitis. Exp Neurol 1999; 160: 508–14 54 Stillman BN, Mischel PS, Baum LG. New roles for galectins in brain tumors-from prognostic markers to therapeutic targets. Brain Pathol 2005; 15: 124–32 55 Kopitz J, Bergmann M, Gabius H-J. How adhesion/growth-regulatory galectins-1 and -3 attain cell specificity: case study defining their target on neuroblastoma cells (SK-N-MC) and marked affinity regulation by affecting microdomain organization of the membrane. IUBMB Life 2010; 62: 624–8 56 Rabinovich GA, Iglesias MM, Modesti NM, Castagna LF, Wolfenstein-Todel C, Riera CM, Sotomayor CE. Activated rat macrophages produce a galectin-1-like protein that induces apoptosis of T cells: biochemical and functional characterization. J Immunol 1998; 160: 4831–40 57 Kurihara D, Ueno M, Tanaka T, Yamashita T. Expression of galectin-1 in immune cells and glial cells after spinal cord injury. Neurosci Res 2010; 66: 265–70 58 López-Lucendo MF, Solís D, Sáiz JL, Kaltner H, Russwurm R, André S, Gabius HJ, Romero A. Homodimeric chicken galectin CG-1B (C-14): crystal structure and detection of unique redox-dependent shape changes involving inter- and intrasubunit disulfide bridges by gel filtration, ultracentrifugation, site-directed mutagenesis and peptide mass fingerprinting. J Mol Biol 2009; 386: 366–78 59 Kopitz J, Russwurm R, Kaltner H, Andre S, Dotti CG, Gabius HJ, Abad-Rodriguez J. Hippocampal neurons and recombinant galectins as tools for systematic carbohydrate structure-function studies in neuronal differentiation. Brain Res Dev Brain Res 2004; 153: 189–96 60 Plachta N, Annaheim C, Bissiere S, Lin S, Ruegg M, Hoving S, Muller D, Poirier F, Bibel M, Barde YA. Identification of a lectin causing the degeneration of neuronal processes using engineered embryonic stem cells. Nat Neurosci 2007; 10: 712–19 61 Horie H, Kadoya T, Sango K, Hasegawa M. Oxidized galectin-1 is an essential factor for peripheral nerve regeneration. Curr Drug Targets 2005; 6: 385–94 62 Ilarregui JM, Croci DO, Bianco GA, Toscano MA, Salatino M, Vermeulen ME, Geffner JR, Rabinovich GA. Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1 driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat Immunol 2009; 10: 981–91 63 Wang J, Lu ZH, Gabius HJ, Rohowsky-Kochan C, Ledeen RW, Wu G. Cross-linking of GM1 ganglioside by galectin-1 mediates regulatory T cell activity involving TRPC5 channel activation: possible role in suppressing experimental autoimmune encephalomyelitis. J Immunol 2009; 182: 4026–45 64 van Horssen J, Brink BP, de Vries HE, van der Valk P, Bo L. The blood-brain barrier in cortical multiple sclerosis lesions. J Neuropathol Exp Neurol 2007; 66: 321–8 65 Tribulatti MV, Cattaneo V, Hellman U, Mucci J, Campetella O. Galectin-8 provides costimulatory and proliferative signals to T lymphocytes. J Leukoc Biol 2009; 86: 371–80 66 Gveric D, Herrera B, Petzold A, Lawrence DA, Cuzner ML. Impaired fibrinolysis in multiple sclerosis: a role for tissue plasminogen activator inhibitors. Brain 2003; 126: 1590–8 67 Eshkar Sebban L, Ronen D, Levartovsky D, Levartovsky D, Elkayam O, Caspi D, Aamar S, Amital H, Rubinow A, Golan I, Naor D, Zick Y. The involvement of CD44 and its novel ligand galectin-8 in apoptotic regulation of autoimmune inflammation. J Immunol 2007; 179: 1225–35 68 Beer A, Andre S, Kaltner H, Lensch M, Franz S, Sarter K, Schulze C, Gaipl US, Kern P, Herrmann M, Gabius HJ. Human galectins as sensors for apoptosis/necrosis-associated surface changes of granulocytes and lymphocytes. Cytometry A 2008; 73: 139–47 69 Cada Z, Smetana K Jr, Lacina L, Plzakova Z, Stork J, Kaltner H, Russwurm R, Lensch M, Andre S, Gabius HJ. Immunohistochemical fingerprinting of the network of seven adhesion/growth-regulatory lectins in human skin and detection of distinct tumour-associated alterations. Folia Biol (Praha) 2009; 55: 145–52 Citing Literature Volume37, Issue6October 2011Pages 654-671 ReferencesRelatedInformation
Publication Year: 2011
Publication Date: 2011-04-19
Language: en
Type: article
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 71
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot